Business, energy, technology, markets and global industry news from Business News Today

NSCLC

PharmaDeviceNews NSCLC
Representative image: Clinician reviewing lung CT scans, reflecting MAIA Biotechnology’s ateganosine data in third-line non-small cell lung cancer and the evolving search for new NSCLC treatment strategies.
Pharma & Biotech

MAIA Biotechnology reports stronger ateganosine data in third-line non-small cell lung cancer

MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in

Read More
Representative image of an oncologist reviewing lung cancer scans with a patient, reflecting Nuvalent’s neladalkib FDA Priority Review and the growing race to develop targeted therapies for ALK-positive non-small cell lung cancer.
Pharma & Biotech

Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves

Nuvalent’s neladalkib has FDA Priority Review in ALK-positive lung cancer. Find out why resistance and brain metastases drive the story.

Read More
Representative image: An oncologist reviews lung scan and precision medicine data, reflecting how Rybrevant plus Lazcluze could reshape first-line treatment expectations for atypical EGFR-mutated non-small cell lung cancer.
Pharma & Biotech

Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?

Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Pharma & Biotech

Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?

Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.

Read More
Representative image of lung cancer immunotherapy research as Innate Pharma advances IPH5201 in the MATISSE Phase 2 trial for resectable non-small cell lung cancer at AACR 2026.
Pharma & Biotech

Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis

Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.

Read More
Pharma & Biotech

Can Prestige Biopharma turn HD204 Phase 3 data into a credible Avastin biosimilar launch?

Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.

Read More
Pharma & Biotech

Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?

Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.

Read More
Pharma & Biotech

Saudi FDA approves ImmunityBio’s ANKTIVA in NSCLC: What this means for immunotherapy 2.0

Find out how ImmunityBio’s subcutaneous immunotherapy ANKTIVA secured Saudi approval for NSCLC and what it means for global immuno-oncology.

Read More
Pharma & Biotech

How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena

Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.

Read More